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BET Signaling: A Novel Therapeutic Target for
Pulmonary Hypertension?
To the Editor:
Pulmonary hypertension (PH) is a progressive clinical condition
with poor prognosis if the patients do not receive adequate
therapy. Recent clinical trials demonstrate that combined therapy
with multiple drugs improves pulmonary arterial hypertension
outcomes more significantly compared with monotherapy (1, 2).
However, there are only three types of drugs targeting PH,
including the nitric oxide–cyclic guanosine monophosphate
pathway, prostacyclin pathway, and endothelin pathway, in
current clinical practice. Thus, introduction of new drugs
targeting novel pathways may provide more combination options,
especially for patients with pulmonary arterial hypertension who
are resistant to or show adverse effects from current drugs. In a
recent issue of the Journal, Van der Feen and colleagues (3) report
that a clinically available BET (bromodomain and extraterminal
motif) inhibitor, RVX-208, shows therapeutic effects on three
preclinical PH models, with reduced pulmonary vascular
resistance, increased cardiac output, and decreased pulmonary
vascular remodeling and inflammation through FoxM1 (forkhead
box protein M1) and PLK1 (polo-like kinase) signaling pathways.
In cultured cells from patients with PH, RVX-208 suppresses
pulmonary artery smooth muscle cell proliferation and endothelial
cell inflammation through FoxM1/PLK1 pathways also. Drugs
targeting these novel pathways have not been used for patients
with PH yet because RVX-208 is now clinically available only
for coronary artery disease. The promising in vivo and in vitro
data from Van der Feen and colleagues suggest that RVX-208
may bring new hope for patients with PH. It is of note that
RVX-208 shows synergistic effects with current PH-target
drugs such as tadalafil and macitentan in PH models, which is
extremely important because combination therapy has been
recommended for patients with PH according to recent guidelines
for PH practice.
However, there are some pitfalls of this study; most of the
PH-target drugs have the side effect of dilating blood vessels in
systemic circulation. Given the fact that most patients with PH have
relatively low blood pressure, it is very important to monitor the
change of blood pressure after administration of PH-target drugs. In
clinical practice, plasma level of BNP (B-type natriuretic peptide)
and right atrial pressure are used to assess the severity and predict
the prognosis of PH. It would be interesting to know the changes of
blood pressure, BNP, and right atrial pressure on the PH animals in
this study. n
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Reply to Chen et al.
From the Authors:
We thank Chen and colleagues for their interest in the BET
(bromodomain and extraterminal motif) inhibitor as a promising
therapeutic target for pulmonary arterial hypertension (PAH).
As mentioned by Chen and colleagues, bringing a new compound
into clinical practice stands on a solid scientific foundation not
only with regard to potential drug efficacy but also with regard
to anticipated side effects.
In the past two decades, we have witnessed the development
of more than 10 drugs either enhancing pathways involved in
vasodilation (nitric oxide–cyclic guanosine monophosphate and
prostacyclin) or antagonizing vasoconstriction (endothelin) in
addition to other pleiotropic effects. Because these processes are
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not unique for the pulmonary circulation, the use of these drugs
may also be accompanied by increased systemic vasodilation,
which at a certain level can be expected to reduce coronary to
right ventricular (RV) perfusion gradient, increase
neurohormonal activation, and diminish left ventricular end-
diastolic pressures, ultimately promoting coronary and systemic
hypoperfusion, increased right-to-left shunting (in case of
intracardiac shunt), and further RV dysfunction through an
enhanced septal shift in a setting of ventricular interdependence
and pericardial constraints (1). Fortunately, except for the
combination of sildenafil and riociguat (2), most studies
confirmed that the limited effect of these vasodilators on systemic
blood pressure was presumably offset by the pulmonary
vasodilation resulting in increased cardiac output. Similarly, the
detrimental effects of more recent therapeutic targets on the RV
may easily be overlooked when the compound under
investigation markedly improves the PAH pulmonary
vasculature. Therefore, recent recommendations suggest that
any new drug developed for PAH should be tested in preclinical
models for its specific effects also on the pressure-overloaded
RV (1, 3).
In humans, RV function is most commonly assessed
using right heart catheterization, echocardiography, and
cardiac magnetic resonance, whereas circulating biomarkers
can serve as a noninvasive surrogate marker (4). In our
recently published multicenter preclinical validation of BET
inhibition for PAH (5), we documented that RVX208, a
clinically available BET inhibitor, mitigates proproliferative,
prosurvival, and proinflammatory pathways in cultured PAH
vascular cells, leading to significant pulmonary histological
and hemodynamic improvements in diverse rat models with
experimentally induced PAH. Not surprisingly, BET inhibition
was associated with significant hemodynamic improvements,
confirming previous results documenting the beneficial effects
of BRD4 inhibition on RV function (6) and coronary perfusion
(7). More importantly, and as previously recommended (1, 3),
we specifically studied the effects of RVX208 treatment in RV
pressure load induced by pulmonary artery banding.
Interestingly, RVX208 was associated with an increase in RV
stroke volume, work, and power, suggesting some
improvements in RV function independent of the afterload,
confirming the safety of the drug during RV compromise
in rats.
Although inhibition of BET impacts diverse cellular
functions and interferes with proproliferative, prosurvival,
procalcific, and proinflammatory pathways, to name a
few, none of those were anticipated to result in changes in
systemic blood pressure. Importantly, in the most recent
cardiovascular outcomes study in 2,425 subjects over 2 years,
apabetalone was not associated with any changes in blood
pressure (8).
Therefore, the published data support the establishment
of a clinical trial with RVX208 in patients with PAH specifically
addressing the safety of BET inhibition in this specific study
population. Based on extensive preclinical and human data,
RVX-208 is not expected to negatively influence RV function
or systemic hemodynamics in human PAH. n
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Québec, Quebec, Canada




Leiden University Medical Center
Leiden, the Netherlands
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Pneumologie de Québec–Université Laval
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